title: Metabolomics in cancer: a bench-to-bedside intersection.
abstract: The field of oncology is a rapidly evolving science mostly due to extensive basic, translational and clinical research which have provided more insights into the tumor biology and set grounds for the development of new therapies. Metabolomics is the upcoming new science in the omics field with the potential to further increment our knowledge of cancer biology. In this review we intend to explore the potential role of metabolomics in understanding cancer process, improving cancer staging, refining tumor characterization and in the search for predictive biomarkers of response and toxicity.
authors.affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA.
authors.forename: Wederson M
authors.initials: WM
authors.lastname: Claudino
authors.forename: Priscila H
authors.initials: PH
authors.lastname: Goncalves
authors.forename: Angelo
authors.initials: A
authors.lastname: di Leo
authors.forename: Philip A
authors.initials: PA
authors.lastname: Philip
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D055808:Drug Discovery; D023281:Genomics; D005838:Genotype; D006801:Humans; D055432:Metabolomics; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D010641:Phenotype; D011379:Prognosis; D057170:Translational Research, Biomedical
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor